References
- European Drug Report. Trends and developments. EMCDDA 2020. pp. 42–47. https://www.google.com/search?client=firefox-b-d&q=european+drug+report+2020.
- Centre for Drugs and Drug Addiction (2020): Drug-related hospital emergency presentations in Europe: update from the Euro-DEN Plus expert network, Technical report, Publications Office of the European Union, Luxembourg, 2020. on-line: https://www.emcdda.europa.eu/system/files/publications/12725/TD02AY20001ENN.pdf.
- National Report to the EMCDDA by the Reitox National Focal Point - 2018. pp 19–22. http://drogfokuszpont.hu/wp-content/uploads/HU_EMCDDA_jelentes_HUNGARY_2018_EN.pdf.
- Persson HE, Sjoberg GK, Haines JA, et al. Poisoning severity score. Grading of acute poisoning. J Toxicol. 1998; 36(3):205–213.
- Kovács K, Kereszty E, Berkecz R, et al. Fatal intoxication of a regular drug user following N-ethyl-hexedrone and ADB-FUBINACA consumption. J Forensic Legal Med. 2019;65:92–100.
- Árok Z, Csesztregi T, Sija É, et al. Changes in illicit, licit and stimulant designer drug use patterns in South-East Hungary between 2008 and 2015. Legal Med. 2017;28:37–44. DOI:10.1016/j.legalmed.2017.07.001
- Institóris L, Tóth AR, Molnár A, et al. Country Report Hungary. In: Prevalence of alcohol and other psychoactive substances in drivers in general traffic Part II: Country reports, DRUID: Driving under the Influence of Drugs, Alcohol and Medicines. EU Project No. TREN-05-FP6TR-S07.61320-518404-DRUID 2011: 90 -107. Available from: https://www.bast.de/Druid/EN/deliverales-list/downloads/Deliverable_2_2_3_Part2.pdf?__blob=publicationFile&v=1
- Körmöczi T, Sija É, Institóris L, et al. Analytical methodologies for the characterization and analysis of the parent compound and phase I metabolites of 4F-MDMB-BICA in human microsome, urine, and blood samples. J Anal Toxicol. 2020;bkab004. DOI: 10.1093/jat/bkab004
- SAS Institute Inc. 2016. SAS/STAT 15.1 User's Guide SAS/STAT Procedures.
- Wouters E, Walraed J, Banister JSD, et al. Insights into biased signaling at cannabinoid receptors: synthetic cannabinoid receptor agonists. Biochem Pharmacol. 2019;169:113623.
- Ligresti A, De Petrocellis L, Di Marzo V. From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic and pathological roles through complex pharmacology. Physiol Rev. 2016;96:1593–1659.
- Volkow ND, Baler RD, Compton WM, et al. Adverse health effects of marijuana use. N Engl J Med. 2014;370(23):2219–2227. DOI:10.1056/NEJMra1402309
- Van der Stelt M, Veldhuis WB, Bar PR, et al. Neuroprotection by delta-9-tetrahydrocannabinol, the main active compound in marijuana, against ouabain-induced in vivo excitotoxicity. J Neurosci. 2001;21(17):6475–6479.
- Gunderson EW. Synthetic cannabinoids: a new frontier of designer dugs. Ann Intern Med. 2013;159(8):563–564.
- Le Boisselier R, Alexandre J, Lelong‐Boulouard V, et al. Focus on cannabinoids and synthetic cannabinoids. Clin Pharmacol Ther. 2017;101(2):220–229. Epub 2016 Dec 20.
- Luethi D, Liechti ME. Designer drugs: mechanism of action and adverse effects. Arch Toxicol. 2020;94:1085–1133.
- Glicksberg L, Kerrigan S. Stability of synthetic cathinones in blood. J Anal Toxicol. 2017;41:711–719.
- Adamowicz P, Malczyk A. Stability of synthetic cathinones in biological materials. For Sci Int. 2019;295:36–45.
- Hermanns-Clausen M, Müller D, Kithinji J, et al. Acute side effects after consumption of the new synthetic cannabinoids AB-CHMINACA and MDMB-CHMICA. Clin Toxicol. 2018;56(6):404–411.
- Adamowicz P. Blood concentrations of synthetic cannabinoids. Clin Toxicol. 2021; 59(3):246–251. Published online 02. Jul.
- Gamage TF, Farquhar CE, McKinnie RJ, et al. Synthetic Cannabinoid Hydroxypentyl Metabolites Retain Efficacy at Human Cannabinoid Receptors. J Pharmacol Exp Ther. 2019;368(3):414–422.